Label: LIFEMS NALOXONE- naloxone hydrochloride kit

  • NDC Code(s): 68599-5804-1, 72336-077-19, 76329-1469-1
  • Packager: Lifsa Drugs LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 26, 2020

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    NALOXONE HYDROCHLORIDE INJECTION, USP

    Opioid Antagonist

    Rx Only

  • DESCRIPTION

    Naloxone hydrochloride, an opioid antagonist, is a synthetic congener of oxymorphone. In structure it differs from oxymorphone in that the methyl group on the nitrogen atom is replaced by an allyl group.

    NALOXONE HYDROCHLORIDE
    (-)-17-Allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride

    IMAGE

    Naloxone hydrochloride occurs as a white to slightly off-white powder, and is soluble in water, in dilute acids, and in strong alkali; slightly soluble in alcohol; practically insoluble in ether and in chloroform.

    Naloxone Hydrochloride Injection is available as a sterile solution for intravenous, intramuscular and subcutaneous administration in 1 mg/mL concentration. pH is adjusted to 3.5 ± 0.5 with hydrochloric acid. Each mL also contains 8.35 mg of sodium chloride. Naloxone Hydrochloride Injection is preservative-free.

  • CLINICAL PHARMACOLOGY

    Complete or Partial Reversal of Opioid Depression

    Naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. Also, it can reverse the psychotomimetic and dysphoric effects of agonist-antagonist such as pentazocine.

    Naloxone hydrochloride is an essentially pure opioid antagonist, i.e., it does not possess the “agonistic” or morphine-like properties characteristic of other opioid antagonists. When administered in usual doses and in the absence of opioids or agonistic effects of other opioid antagonists, it exhibits essentially no pharmacologic activity.

    Naloxone hydrochloride has not been shown to produce tolerance or cause physical or psychological dependence. In the presence of physical dependence on opioids, naloxone hydrochloride will produce withdrawal symptoms. However, in the presence of opioid dependence, opiate withdrawal symptoms may appear within minutes of naloxone hydrochloride administration and subside in about 2 hours. The severity and duration of the withdrawal syndrome are related to the dose of naloxone hydrochloride and to the degree and type of opioid dependence.
    While the mechanism of action of naloxone hydrochloride is not fully understood, in vitro evidence suggests that naloxone hydrochloride antagonizes opioid effects by competing for the μ, κ and σ opiate receptor sites in the CNS, with the greatest affinity for the μ receptor.

    When naloxone hydrochloride is administered intravenously (I.V.), the onset of action is generally apparent within two minutes. The onset of action is slightly less rapid when it is administered subcutaneously (S.C.) or intramuscularly (I.M.). The duration of action is dependent upon the dose and route of administration of naloxone hydrochloride. Intramuscular administration produces a more prolonged effect than intravenous administration. Since the duration of action of naloxone hydrochloride may be shorter than that of some opiates, the effect of the opiate may return as the effects of naloxone hydrochloride dissipates. The requirement for repeat doses of naloxone hydrochloride will also be dependent upon the amount, type and route of administration of the opioid being antagonized.

    Adjunctive Use in Septic Shock

    Naloxone hydrochloride has been shown in some cases of septic shock to produce a rise in blood pressure that may last up to several hours; however, this pressure response has not been demonstrated to improve patient survival. In some studies, treatment with naloxone hydrochloride in the setting of septic shock has been associated with adverse effects, including agitation, nausea and vomiting, pulmonary edema, hypotension, cardiac arrhythmias, and seizures. The decision to use naloxone hydrochloride in septic shock should be exercised with caution, particularly in patients who may have underlying pain or have previously received opioid therapy and may have developed opioid tolerance.

    Because of the limited number of patients who have been treated, optimal dosage and treatment regimens have not been established.

  • PHARMACOKINETICS

    Distribution

    Following parenteral administration, naloxone hydrochloride is rapidly distributed in the body and readily crosses the placenta. Plasma protein binding occurs but is relatively weak. Plasma albumin is the major binding constituent but significant binding of naloxone also occurs to plasma constituents other than albumin. It is not known whether naloxone is excreted into human milk.

    Metabolism and Elimination

    Naloxone hydrochloride is metabolized in the liver, primarily by glucuronide conjugation with naloxone-3-glucoronide as the major metabolite. In one study the serum half-life in adults ranged from 30 to 81 minutes (mean 64 ± 12 minutes). In a neonatal study the mean plasma half-life was observed to be 3.1 ± 0.5 hours. After an oral or intravenous dose, about 25-40% of the drug is excreted as metabolites in urine within 6 hours, about 50% in 24 hours, and 60-70% in 72 hours.

  • INDICATIONS AND USAGE

    Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage.

    Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock. (see CLINICAL PHARMACOLOGY; Adjunctive Use in Septic Shock).

  • CONTRAINDICATIONS

    Naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to it or to any of the other ingredients in naloxone hydrochloride.

  • WARNINGS

    Drug Dependence

    Naloxone hydrochloride should be administered cautiously to persons including newborns of mothers who are known or suspected to be physically dependent on opioids. In such cases an abrupt and complete reversal of opioid effects may precipitate an acute withdrawal syndrome.
    The signs and symptoms of opioid withdrawal in a patient physically dependent on opioids may include, but are not limited to, the following: body aches, diarrhea, tachycardia, fever, runny nose, sneezing, piloerection, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, abdominal cramps, weakness, and increased blood pressure. In the neonate, opioid withdrawal may also include: convulsions, excessive crying, and hyperactive reflexes.

    Repeat Administration

    The patient who has satisfactorily responded to naloxone hydrochloride should be kept under continued surveillance and repeated doses of naloxone hydrochloride should be administered, as necessary, since the duration of action of some opioids may exceed that of naloxone hydrochloride.

    Respiratory Depression due to Other Drugs

    Naloxone hydrochloride is not effective against respiratory depression due to non-opioid drugs and in the management of acute toxicity caused by levopropoxyphene. Reversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete or require higher doses of naloxone. If an incomplete response occurs, respirations should be mechanically assisted as clinically indicated.

  • PRECAUTIONS

    General

    In addition to naloxone hydrochloride, other resuscitative measures such as maintenance of a free airway, artificial ventilation, cardiac massage, and vasopressor agents should be available and employed when necessary to counteract acute opioid poisoning.
    Abrupt postoperative reversal of opioid depression may result in nausea, vomiting, sweating, tremulousness, tachycardia, increased blood pressure, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest which may result in death. Excessive doses of naloxone hydrochloride in postoperative patients may result in significant reversal of analgesia and may cause agitation (see PRECAUTIONS and DOSAGE AND ADMINISTRATIONUsage in Adults-Postoperative Opioid Depression).

    Several instances of hypotension, hypertension, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest have been reported in postoperative patients. Death, coma, and encephalopathy have been reported as sequelae of these events. These have occurred in patients most of whom had preexisting cardiovascular disorders or received other drugs which may have similar adverse cardiovascular effects. Although a direct cause and effect relationship has not been established, naloxone hydrochloride should be used with caution in patients with preexisting cardiac disease or patients who have received medications with potential adverse cardiovascular effects, such as hypotension, ventricular tachycardia or fibrillation, and pulmonary edema. It has been suggested that the pathogenesis of pulmonary edema associated with the use of naloxone hydrochloride is similar to neurogenic pulmonary edema, i.e., a centrally mediated massive catecholamine response leading to a dramatic shift of blood volume into the pulmonary vascular bed resulting in increased hydrostatic pressures.

    Drug Interactions

    Large doses of naloxone are required to antagonize buprenorphine since the latter has a long duration of action due to its slow rate of binding and subsequent slow dissociation from the opioid receptor. Buprenorphine antagonism is characterized by a gradual onset of the reversal effects and a decreased duration of action of the normally prolonged respiratory depression. The barbiturate methohexital appears to block the acute onset of withdrawal symptoms induced by naloxone in opiate addicts.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies in animals to assess the carcinogenic potential of naloxone hydrochloride have not been conducted. Naloxone hydrochloride was weakly positive in the Ames mutagenicity and in the in vitro human lymphocyte chromosome aberration test but was negative in the in vitro Chinese hamster V79 cell HGPRT mutagenicity assay and in the in vivo rat bone marrow chromosome aberration study.

    Reproduction studies conducted in mice and rats at doses 4-times and 8-times, respectively, the dose of a 50 kg human given 10 mg/day (when based on surface area or mg/m2), demonstrated no embryotoxic or teratogenic effects due to naloxone hydrochloride.

    Use in Pregnancy

    Teratogenic Effects: Pregnancy Category C: Teratology studies conducted in mice and rats at doses 4-times and 8-times, respectively, the dose of a 50 kg human given 10 mg/day (when based on surface area or mg/m2), demonstrated no embryotoxic or teratogenic effects due to naloxone hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, naloxone hydrochloride should be used during pregnancy only if clearly needed.

    Non-teratogenic Effects: Risk-benefit must be considered before naloxone hydrochloride is administered to a pregnant woman who is known or suspected to be opioid-dependent since maternal dependence may often be accompanied by fetal dependence. Naloxone crosses the placenta, and may precipitate withdrawal in the fetus as well as in the mother. Patients with mild to moderate hypertension who receive naloxone during labor should be carefully monitored as severe hypertension may occur.

    Use in Labor and Delivery

    It is not known if naloxone hydrochloride affects the duration of labor and/or delivery. However, published reports indicated that administration of naloxone during labor did not adversely affect maternal or neonatal status.

    Nursing Mothers: It is not known whether naloxone is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when naloxone is administered to a nursing woman.

    Pediatric Use

    Naloxone hydrochloride injection, USP may be administered intravenously, intramuscularly or subcutaneously in children and neonates to reverse the effects of opiates. The American Academy of Pediatrics, however, does not endorse subcutaneous or intramuscular administration in opiate intoxication since absorption may be erratic or delayed. Although the opiate-intoxicated child responds dramatically to naloxone hydrochloride, he/she must be carefully monitored for at least 24 hours as a relapse may occur as naloxone is metabolized.

    When naloxone hydrochloride is given to the mother shortly before delivery, the duration of its effect lasts only for the first two hours of neonatal life. It is preferable to administer naloxone hydrochloride directly to the neonate if needed after delivery. Naloxone hydrochloride has no apparent benefit as an additional method of resuscitation in the newly born infant with intrauterine asphyxia which is not related to opioid use.

    Usage in Pediatric Patients and Neonates for Septic Shock: The safety and effectiveness of naloxone hydrochloride in the treatment of hypotension in pediatric patients and neonates with septic shock have not been established. One study of two neonates in septic shock reported a positive pressor response; however, one patient subsequently died after intractable seizures.

    Geriatric Use

    Clinical studies of naloxone hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    Renal Insufficiency/Failure

    The safety and effectiveness of naloxone hydrochloride in patients with renal insufficiency/failure have not been established in well-controlled clinical trials. Caution should be exercised when naloxone hydrochloride is administered to this patient population.

    Liver Disease

    The safety and effectiveness of naloxone hydrochloride in patients with liver disease have not been established in well-controlled clinical trials. Caution should be exercised when naloxone hydrochloride is administered to patients with liver disease.

  • ADVERSE REACTIONS

    Postoperative

    The following adverse events have been associated with the use of naloxone hydrochloride in postoperative patients: hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as sequelae of these events. Excessive doses of naloxone hydrochloride in postoperative patients may result in significant reversal of analgesia and may cause agitation (see PRECAUTIONS and DOSAGE AND ADMINISTRATIONUsage in Adults-Postoperative Opioid Depression).

    Opioid Depression

    Abrupt reversal of opioid depression may result in nausea, vomiting, sweating, tachycardia, increased blood pressure, tremulousness, seizures, ventricular tachycardia and fibrillation, pulmonary edema, and cardiac arrest which may result in death (see PRECAUTIONS).

    Opioid Dependence

    Abrupt reversal of opioid effects in persons who are physically dependent on opioids may precipitate an acute withdrawal syndrome which may include, but is not limited to, the following signs and symptoms: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, tachycardia. In the neonate, opioid withdrawal may also include: convulsions; excessive crying; hyperactive reflexes (see WARNINGS).
    Adverse events associated with the postoperative use of naloxone hydrochloride are listed by organ system and in decreasing order of frequency as follows:

    Cardiac Disorders: pulmonary edema, cardiac arrest or failure, tachycardia, ventricular fibrillation, and ventricular tachycardia. Death, coma, and encephalopathy have been reported as sequelae of these events.
    Gastrointestinal Disorders:vomiting, nausea
    Nervous System Disorders: convulsions, paraesthesia, grand mal convulsion
    Psychiatric Disorders: agitation, hallucination, tremulousness
    Respiratory, Thoracic and Mediastinal Disorders:dyspnea, respiratory depression, hypoxia
    Skin and Subcutaneous Tissue Disorders:nonspecific injection site reactions, sweating
    Vascular Disorders: hypertension, hypotension, hot flushes or flushing.

    See also PRECAUTIONS and DOSAGE AND ADMINISTRATIONUsage in Adults; Postoperative Opioid Depression.

  • DRUG ABUSE AND DEPENDENCE

    Naloxone hydrochloride is an opioid antagonist. Physical dependence associated with the use of naloxone hydrochloride has not been reported. Tolerance to the opioid antagonist effect of naloxone hydrochloride is not known to occur.

  • OVERDOSAGE

    There is limited clinical experience with naloxone hydrochloride overdosage in humans.

    Adult Patients

    In one small study, volunteers who received 24 mg/70 kg did not demonstrate toxicity. In another study, 36 patients with acute stroke received a loading dose of 4 mg/kg (10 mg/m2/min) of naloxone hydrochloride followed immediately by 2 mg/kg/hr for 24 hours. Twenty-three patients experienced adverse events associated with naloxone use, and naloxone was discontinued in seven patients because of adverse effects. The most serious adverse events were: seizures (2 patients), severe hypertension (1), and hypotension and/or bradycardia (3).

    At doses of 2 mg/kg in normal subjects, cognitive impairment and behavioral symptoms, including irritability, anxiety, tension, suspiciousness, sadness, difficulty concentrating, and lack of appetite have been reported. In addition, somatic symptoms, including dizziness, heaviness, sweating, nausea, and stomachaches were also reported. Although complete information is not available, behavioral symptoms were reported to often persist for 2-3 days.

    Pediatric Patients

    Up to 11 doses of 0.2 mg of naloxone (2.2 mg) have been administered to children following overdose of diphenoxylate hydrochloride with atropine sulfate. Pediatric reports include a 2-1/2 year-old child who inadvertently received a dose of 20 mg of naloxone for treatment of respiratory depression following overdose with diphenoxylate hydrochloride with atropine sulfate. The child responded well and recovered without adverse sequelae. There is also a report of a 4-1/2 year-old child who received 11 doses during a 12-hour period, with no adverse sequelae.

    Patient Management

    Patients who experience a naloxone hydrochloride overdose should be treated symptomatically in a closely supervised environment.

    Physicians should contact a poison control center for the most up-to-date patient management information.

  • DOSAGE AND ADMINISTRATION

    Naloxone hydrochloride injection may be administered intravenously, intramuscularly, or subcutaneously. The most rapid onset of action is achieved by intravenous administration, which is recommended in emergency situations.

    Since the duration of action of some opioids may exceed that of naloxone, the patient should be kept under continued surveillance. Repeated doses of naloxone should be administered, as necessary.

    Intravenous Infusion

    Naloxone hydrochloride injection may be diluted for intravenous infusion in normal saline or 5% dextrose solutions. The addition of 2 mg of naloxone in 500 mL of either solution provides a concentration of 0.004 mg/mL. Mixtures should be used within 24 hours. After 24 hours, the remaining unused mixture must be discarded. The rate of administration should be titrated in accordance with the patient’s response.
    Naloxone hydrochloride injection should not be mixed with preparations containing bisulfite, metabisulfite, long-chain or high molecular weight anions, or any solution having an alkaline pH. No drug or chemical agent should be added to naloxone hydrochloride injection unless its effect on the chemical and physical stability of the solution has first been established.

    General

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

    Usage in Adults

    Opioid Overdose—Known or Suspected: An initial dose of 0.4 mg to 2 mg of naloxone hydrochloride may be administered intravenously. If the desired degree of counteraction and improvement in respiratory functions are not obtained, it may be repeated at two-to-three-minute intervals. If no response is observed after 10 mg of naloxone hydrochloride have been administered, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questioned. Intramuscular or subcutaneous administration may be necessary if the intravenous route is not available.

    Postoperative Opioid Depression: For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of naloxone hydrochloride are usually sufficient. The dose of naloxone hydrochloride should be titrated according to the patient’s response. For the initial reversal of respiratory depression, naloxone hydrochloride should be injected in increments of 0.1 to 0.2 mg intravenously at two-to three-minute intervals to the desired degree of reversal—i.e., adequate ventilation and alertness without significant pain or discomfort. Larger than necessary dosage of naloxone may result in significant reversal of analgesia and increase in blood pressure. Similarly, too rapid reversal may induce nausea, vomiting, sweating, or circulatory stress.
    Repeat doses of naloxone may be required within one- to two-hour intervals depending upon the amount, type (i.e., short or long acting) and time interval since last administration of opioid. Supplemental intramuscular doses have been shown to produce a longer lasting effect.

    Septic Shock:The optimal dosage of naloxone hydrochloride or duration of therapy for the treatment of hypotension in septic shock patients has not been established (see CLINICAL PHARMACOLOGY).

    Usage in Children

    Opioid Overdose—Known or Suspected:The usual initial dose in children is 0.01 mg/kg body weight given I.V. If this dose does not result in the desired degree of clinical improvement, a subsequent dose of 0.1 mg/kg body weight may be administered. If an l.V. route of administration is not available, naloxone may be administered I.M. or S.C. in divided doses. If necessary, naloxone hydrochloride injection can be diluted with sterile water for injection.

    Postoperative Opioid Depression: Follow the recommendations and cautions under Adult Postoperative Depression. For the initial reversal of respiratory depression naloxone hydrochloride should be injected in increments of 0.005 mg to 0.01 mg intravenously at two- to three-minute intervals to the desired degree of reversal.

    Usage in Neonates
    Opioid-lnduced Depression: The usual initial dose is 0.01 mg/kg body weight administered I.V., I.M., or S.C. This dose may be repeated in accordance with adult administration guidelines for postoperative opioid depression.

  • HOW SUPPLIED

    1 mg/mL naloxone hydrochloride injection USP, for intravenous, intramuscular and subcutaneous administration.

    Available as follows:

    1 mg/mL

    2 mL single dose disposable prefilled syringes, in the MIN-I-JET® system with 21 G. x 11/2” needle. Shrink Wrapped Packages of 10.

         NDC 76329-1469-1      Stock No. 1469 (contains no preservative)

    Syringe Assembly Directions:

    The MIN-I-JET® syringe with needle, illustrated below, is the basic unit upon which all the other syringe systems are built; slight adaptations and/ or additional auxiliary parts create the other syringe systems. Assembly directions remain essentially the same.

    USE ASEPTIC TECHNIQUE

    Do not assemble until ready to use.

    IMAGE

    *CAUTION: IMPROPER ENGAGING MAY CAUSE GLASS BREAKAGE AND SUBSEQUENT INJURY.

  • SPL UNCLASSIFIED SECTION

    Store at 25˚C (77˚F); excursions permitted to 15˚-30˚C (59˚-86˚F). [See USP Controlled Room Temperature.]
    Protect from light.
    Store in carton until contents have been used.

    INTERNATIONAL MEDICATION SYSTEMS, LIMITED
    SO. EL MONTE, CA 91733, U.S.A.                            REV. 11-13

    An Amphastar Pharmaceuticals Company

    © INTERNATIONAL MEDICATION SYSTEMS, LIMITED 2013

  • Drug Facts

    MCKESSON ALCOHOL PREP PAD- isopropyl alcohol swab

  • Active ingredient

    Isopropyl Alcohol 70% v/v

  • Purpose

    First Aid Antiseptic

  • Use

    For preparation of the skin prior to an injection

  • Warnings

    • For external use only
    • Flammable, keep away from fire or flame

    Do not use

    • Do not use with electrocautery procedures
    • Do not use in the eyes
    • Do not apply to irritated skin
    • Stop use if pain, irritation, redness, or swelling occurs, discontinue use and consult a physician.

    Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

  • Directions

    • Open packet
    • Remove pad
    • Apply topically as needed to cleanse intended area. Discard after single use.
  • Other information

    • Store at room temperature 59-86°F (15-30°C)
    • Contents sterile in unopened, undamaged package
  • Inactive ingredients

    purified water

  • SPL UNCLASSIFIED SECTION

    Instructions For Use

    LifEMS Naloxone

    Naloxone Convenience Kit

    Rx Only

    NDC 72336-077-19

    Single use only

    For intravenous, intramuscular or subcutaneous use. Not for ophthalmic use.

    Keep out of reach of children

    STORE AT 25°C (77°F); EXCURSIONS PERMITTED TO 15°C - 30°C (59°F- 86°F)

  • Indications and Use

    Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock.

    Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including, propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine and butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone hydrochloride injection may be useful as an adjunctive agent to increase blood pressure in the management of septic shock.

  • Dosage and Administration

    Use as prescribed by your healthcare professional and refer to the package insert and medication guide for more information on dosing and administration. Use as prescribed by your healthcare professional and refer to the package insert and medication guide for more information on dosing and administration.

  • Product information

    LifEMS Naloxone is a naloxone convenience kit designed to treat a single episode of an opioid overdose. The naloxone provided in this kit must be used on the patient experiencing signs and symptoms of an overdose. The needle should be discarded in an appropriate sharps container.

    Each LifEMS Naloxone kit contains:
    (1) Naloxone Hydrochloride USP injection (1 mg/mL) 2 mL single dose disposable prefilled syringe in a MINI-I-JET® syringe with a 21 G. X 1-1/2 needle
    (2) Alcohol pads for administration.
    (1) Naloxone package insert
    (1) Instructions for Use Card
    SINGLE DOSE/ NO PRESERVATIVE ADDED/ PROTECT FROM LIGHT / STORE AT 25°C (77°F);EXCURSIONS PERMITTED TO 15°C - 30°C (59°F- 86°F). [SEE USP CONTROLLED ROOM TEMPERATURE]. / FOR IV, IM OR SC USE AS AN OPIOID ANTAGONIST/USUAL DOSAGE:SEE INSERT.

    See naloxone package insert for INDICATIONS, and USAGE, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and OVERDOSAGE.*

  • Instructions for Use

    Remove contents from outer packaging and place on a flat surface. Remove the naloxone syringe from its original packaging. Always follow the prescriber’s order for dosing information. Using aseptic techniques assemble the syringe

    (DO NOT ASSEMBLE UNTIL READY TO USE)

    1. Remove protective caps. Align vial such that the injector needle is centered on the stopper.

    IMAGE

    2. Thread vial into injector 3 half turns, or until needle penetrates stopper. CAUTION: IMPROPER ENGAGING MAY CAUSE GLASS BREAKING AND SUBSEQUENT INJURY.

    IMAGE

    DO NOT PUSH VIAL INTO INJECTOR; THIS MAY CAUSE MISALIGNMENT.

    3. Prepare to administer the subcutaneous or intramuscular injection. The preferred site of the naloxone administration is the anterolateral aspect of the thigh (vastus lateralis muscle) because of its location, size and available blood flow. The location is between the greater trochanter and the knee. When injecting, life the vastus lateralis muscle away from the bone. Cleanse the site of administration with the alcohol pad provided, however, naloxone may be injected through clothing if necessary.

    4. Remove the needle cover from the naloxone syringe and expel air. The injection is now ready for use.

    IMAGE

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/Safety/MedWatch or call 1-800-FDA-1088

  • Packaging

    KIT COMPONENTS LABEL

    PRINCIPLE DISPLAY PANEL: Vial Label (Stock No. 1469)
    IMS, LIMITED
    So. El Monte, CA 91733, U.S.A.
    7633690B 8-11
    2 mL 2 mg 1 mg / mL
    NALOXONE HYDROCHLORIDE INJECTION, USP
    FOR I.M., I.V. OR
    S.C. USE / SINGLE DOSE
    SEE INSERT
    Rx Only

    IMAGE

    PRINCIPLE DISPLAY PANEL: Carton (Stock No. 1469))
    MIN-I-JET®
    Prefilled Syringe
    Rx Only
    NDC 76329-1469-1
    STOCK NO. 1469
    NALOXONE HYDROCHLORIDE INJ., USP
    (1 mg/mL)
    2 mg per 2 mL
    FOR INTRAVENOUS, INTRAMUSCULAR OR SUBCUTANEOUS USE / AN OPIOID ANTAGONIST
    MIN-I-JET®
    21 G. X 1-1/2" NEEDLE
    2 mL single dose disposable prefilled syringe
    Single use, do not reuse or resterilize.

    IMAGE

  • PRINCIPAL DISPLAY PANEL – PACKET LABELNDC 68599-5804-1MCKESSONAlcohol Prep PadSTERILE | SATURATED WITH70% v/v ISOPROPYL ALCOHOL1.2" x 2.6"(3 cm x 6.5 cm)DO NOTREUSEMFR# 58-204

    IMAGE

  • PRINCIPAL DISPLAY PANEL – Carton LabelNDC 72336-077-01Rx OnlyCONTAINS THE MIN-I-JET® SYRINGE. Lifsa PharmaKeep out of reach of children.For intravenous, intramuscular or subcutaneous use. Not for opthalmic use. Single Use Only.Naloxone is light sensitive; protect from light.Kit contains:Naloxone Hydrochloride USP injection (1 mg/mL) 2 mL single dose disposable prefilled syringe in a MINI-JET® syringe and alcohol pads for administration.Naloxone Hydrochloride 2 mg/2 mLLifEms NaloxoneNALOXONE CONVENIENCE KIT

    IMAGE

  • INGREDIENTS AND APPEARANCE
    LIFEMS NALOXONE 
    naloxone hydrochloride kit
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:72336-077
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:72336-077-191 in 1 CARTON; Type 0: Not a Combination Product11/20/2020
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 110 SYRINGE 20 mL
    Part 22 PACKET 2 mL
    Part 1 of 2
    NALOXONE HYDROCHLORIDE 
    naloxone hydrochloride injection
    Product Information
    Item Code (Source)NDC:76329-1469
    Route of AdministrationPARENTERAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    NALOXONE HYDROCHLORIDE (UNII: F850569PQR) (NALOXONE - UNII:36B82AMQ7N) NALOXONE HYDROCHLORIDE1 mg  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:76329-1469-110 in 1 BOX
    12 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07207604/01/1988
    Part 2 of 2
    MCKESSON ALCOHOL PREP PAD 
    isopropyl alcohol swab
    Product Information
    Item Code (Source)NDC:68599-5804
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ISOPROPYL ALCOHOL (UNII: ND2M416302) (ISOPROPYL ALCOHOL - UNII:ND2M416302) ISOPROPYL ALCOHOL0.7 mL  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:68599-5804-11 mL in 1 PACKET; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    OTC monograph not finalpart333A04/09/2010
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07207611/20/2020
    Labeler - Lifsa Drugs LLC (081205160)